Abstract

People with hypertension are more prone to incur depressive symptoms, while depressive symptoms have an obvious influence on the healthy functioning, treatment, and management of hypertensive patients. However, there have been limited studies on the association between depression and the economic burden of hypertension. We used data from the 2018 China Health and Retirement Longitudinal Study (CHARLS) to estimate the additional annual direct and indirect economic burden of depressive symptoms among middle-aged and elderly hypertensive patients with a multivariable regression model. The depressive symptoms were associated with substantial additional direct and indirect economic burden. Compared with non-co-MHDS (non-co-morbid hypertension and depressive symptoms) patients, the direct economic burden of lower co-MHDS (co-morbid hypertension and depressive symptoms) patients and higher co-MHDS patients increased 1887.4 CNY and 5508.4 CNY, respectively. For indirect economic burden, the lower co-MHDS patients increased 331.2 CNY and the higher co-MHDS patients increased 636.8 CNY. Both direct and indirect economic burden were incremental with the aggravation of depressive symptoms. The results showed depressive symptoms increased total healthcare costs by increasing the utilization and expenditure of primary healthcare services. Depressive symptoms also led to economic loss of productivity, especially for agricultural workers. This study highlights the importance of mental healthcare for hypertensive patients.

Highlights

  • IntroductionThe burden of depression is expected to increase to 5.7% of the global disease burden by 2020 and major depression will rank as the first cause of disease burden worldwide by 2030 [2]

  • Our study found depressive symptoms were associated with additional direct economic burden on middle-aged and elderly hypertensive patients, and the economic loss was positively associated with depressive level

  • To direct economic burden, we found depressive symptoms were associated with increased additional indirect economic burden on middle-aged and elderly hypertensive patients, and the economic loss was mainly presented as agricultural productivity loss

Read more

Summary

Introduction

The burden of depression is expected to increase to 5.7% of the global disease burden by 2020 and major depression will rank as the first cause of disease burden worldwide by 2030 [2]. A meta-analysis study showed the prevalence of depression in people with hypertension was 26.8%, higher than that in the general population [3]. Hypertensive patients are vulnerable to psychological distress due to side effects of antihypertensive drugs, decreased quality of life, and health impairment [6]. There are a great deal of studies indicating that depressive disorders have obvious impacts on hypertensive patients [9,10]. Depression and anxiety disorders can affect antihypertensive medication adherence and therapeutic effects [11,12].

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call